Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Nicotinamide Phosphoribosyltransferase Pipeline Review H2 2016: Latest Therapeutics Market Analysis

Thursday, November 3, 2016 4:27
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Latest Nicotinamide Phosphoribosyltransferase Pipeline Review, H2 2016, provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.
 

Nicotinamide Phosphoribosyltransferase therapeutics industry report provides comprehensive information on the therapeutics under development for Nicotinamide Phosphoribosyltransferase, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotinamide Phosphoribosyltransferase and features dormant and discontinued projects.
 

Browse more detail information about Nicotinamide Phosphoribosyltransferase market report at: http://www.absolutereports.com/nicotinamide-phosphoribosyltransferase-visfatin-or-pre-b-cell-colony-enhancing-factor-1-or-nampt-or-ec-2-4-2-12-pipeline-review-h2-2016-10393276

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Nicotinamide Phosphoribosyltransferase – Pipeline Review, H2 2016:

  • Angelini Group
  • Aurigene Discovery Technologies Limited
  • Calico LLC
  • FORMA Therapeutics, Inc.
  • Genentech, Inc.
  • Karyopharm Therapeutics, Inc.
  • OncoTartis, Inc.

Get a PDF Sample of Nicotinamide Phosphoribosyltransferase Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10393276

Drug Profiles of Included in Nicotinamide Phosphoribosyltransferase Therapeutics Development Market Report

  • P7-C3A20
  • Small Molecules to Inhibit NAMPT for Cancer
  • Small Molecules to Inhibit NAMPT for Oncology
  • STF-118804
     

And other drug profiles
Have any query? ask our expert @
http://www.absolutereports.com/enquiry/pre-order-enquiry/10393276

Key Topics Covered:
1.Introduction
2.Nicotinamide Phosphoribosyltransferase Overview
3.Nicotinamide Phosphoribosyltransferase Therapeutics Development
4.Pipeline Products for Nicotinamide Phosphoribosyltransferase – Overview
5.Pipeline Products for Nicotinamide Phosphoribosyltransferase – Comparative Analysis
6.Nicotinamide Phosphoribosyltransferase – Therapeutics under Development by Companies
7.Nicotinamide Phosphoribosyltransferase – Therapeutics under Investigation by Universities/Institutes
8.Nicotinamide Phosphoribosyltransferase Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Nicotinamide Phosphoribosyltransferase – Products under Development by Companies
13.Nicotinamide Phosphoribosyltransferase – Products under Investigation by Universities/Institutes
14.Nicotinamide Phosphoribosyltransferase – Companies Involved in Therapeutics Development
15.Nicotinamide Phosphoribosyltransferase Drug Profiles
16.Nicotinamide Phosphoribosyltransferase Dormant Projects
17.Nicotinamide Phosphoribosyltransferase Discontinued Products
18.Nicotinamide Phosphoribosyltransferase Featured News & Press Releases

Jun 22, 2016: Karyopharm Initiates Phase 1 Clinical Trial with KPT-9274 43

Mar 16, 2016: Karyopharm to Present Data on Oncology drug KPT-9274 at the 2016 American Association for Cancer Research Annual Meeting 44

Apr 18, 2015: Aurigene to Present its NAMPT Inhibitors Programs at AACR 2015 45

Nov 01, 2013: Novel drug discovery method designed by Stanford scientists 45

Apr 02, 2013: Aurigene To Present Poster On NAMPT Inhibitor Program At AACR 2013 46
And Continue…
 

Get Discount on Nicotinamide PhosphoribosyltransferaseMarket Research Report at: http://www.absolutereports.com/enquiry/request-discount/10393276

This 48 pages research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Nicotinamide Phosphoribosyltransferase
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nicotinamide Phosphoribosyltransferase pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact–

Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email – sales@absolutereports.com

www.absolutereports.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.